Dyne Therapeutics (NASDAQ:DYN) Trading Down 4.2% - What's Next?

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report)'s share price fell 4.2% during mid-day trading on Tuesday . The company traded as low as $11.88 and last traded at $11.87. 129,341 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 1,352,046 shares. The stock had previously closed at $12.39.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and set a $46.00 price objective on shares of Dyne Therapeutics in a research note on Monday, March 17th. Raymond James upgraded Dyne Therapeutics to a "strong-buy" rating in a research report on Thursday, December 12th. BMO Capital Markets began coverage on Dyne Therapeutics in a research report on Wednesday, March 12th. They set an "outperform" rating and a $50.00 target price for the company. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $45.00 price target on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Finally, Guggenheim reissued a "buy" rating on shares of Dyne Therapeutics in a report on Friday, January 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Dyne Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $47.46.

Dyne Therapeutics Trading Down 3.0 %

The company's fifty day simple moving average is $13.27 and its 200 day simple moving average is $23.52. The firm has a market capitalization of $1.30 billion, a P/E ratio of -3.22 and a beta of 1.11.

Remove Ads

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.04. On average, analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the transaction, the insider now owns 199,087 shares in the company, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 6,237 shares of company stock worth $77,760 over the last ninety days. 20.77% of the stock is owned by corporate insiders.

Institutional Trading of Dyne Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of DYN. Bank of New York Mellon Corp grew its holdings in shares of Dyne Therapeutics by 0.3% during the fourth quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company's stock valued at $5,532,000 after buying an additional 698 shares during the last quarter. Summit Investment Advisors Inc. lifted its position in shares of Dyne Therapeutics by 9.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock valued at $203,000 after acquiring an additional 721 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Dyne Therapeutics in the third quarter worth $34,000. KBC Group NV grew its position in shares of Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after purchasing an additional 978 shares in the last quarter. Finally, Virtue Capital Management LLC increased its position in Dyne Therapeutics by 4.4% in the third quarter. Virtue Capital Management LLC now owns 23,208 shares of the company's stock worth $834,000 after purchasing an additional 981 shares during the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.